Geron announces removal of Full Clinical Hold on Imetelstat The full clinical hold on Geron’s sole pipeline candidate, investigation new drug (IND), Imetelstat, has been lifted by the FDA. The company does not intend to conduct further studies or develop imetelstat for the treatment of essential thrombocythemia (ET) or polycythemia vera (PV). The development plan […]
Imetelstat Trials for MF moves forward as FDA removes hold
Geron Corp announced today that the partial clinical hold on clinical trials of imetelstat in myelofibrosis has been removed by the FDA. The hold for essential thrombocythemia and polycythemia vera remains. Click here for the full story.
